Company / SG&A Expense
Serina Therapeutics, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$11.0M
FY2025
5-year range
$3.9M / $11.0M
FY2021-FY2025
Trend
+182.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $4M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +6.2%.
Increased from $4M to $11M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +22.6%
- 5-Year CAGR
- +6.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 182.4% year-over-year.
- Lowest sg&a expense in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.0M | +182.4% |
| FY2024 | $3.9M | +0.0% |
| FY2023 | $3.9M | -34.8% |
| FY2022 | $6.0M | -11.0% |
| FY2021 | $6.7M | -17.6% |
| FY2020 | $8.1M | +44.1% |
| FY2018 | $5.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026